The Behavioral Wire Briefing — a weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next across pharma, psychedelics, cannabis, digital health, regulation, markets, and research.
Coverage of academic research, clinical trials, and methodological developments across mental health.
Federal money for psychedelics went from nothing to a real portfolio in two years. It is not a copy of the company pipeline. The NIH is funding the questions private capital has structural reasons to skip.
Deuteration replaces a hydrogen atom with its heavier isotope to slow a specific step of metabolism. It is a precision pharmacokinetic tool, not a new mechanism, and it has become a favored way to re-engineer known psychiatric molecules. Here is what it does, what it has already done, and what it cannot do.
A decade of breakthroughs, advisory committee meetings, draft guidance documents, and one rejection. The agency's position has been consistent in ways the field has been slow to acknowledge, and the current voucher moment makes more sense read against the full record than against any individual moment.
The two concepts are routinely conflated, and the conflation has cost the field a decade. Why blinding fails in psychedelic trials, why expectancy is a separate and harder problem, and what trial designs actually solve for it.
An evergreen reference on what actually matters in a psychedelic-assisted therapy trial readout: blinding analyses, expectancy controls, dose-response designs, and the questions to ask before you trust the headline number.